Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion

被引:62
|
作者
Barber, DF
Bartolomé, A
Hernandez, C
Flores, JM
Fernandez-Arias, C
Rodríguez-Borlado, L
Hirsch, E
Wymann, M
Balomenos, D
Carrera, AC
机构
[1] Univ Autonoma Madrid, Dept Immunol & Oncol, E-28049 Madrid, Spain
[2] Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Anim Facil, E-28049 Madrid, Spain
[3] Univ Complutense Madrid, Sch Vet, Dept Anim Med & Surg, E-28040 Madrid, Spain
[4] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy
[5] Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland
来源
JOURNAL OF IMMUNOLOGY | 2006年 / 176卷 / 01期
关键词
D O I
10.4049/jimmunol.176.1.589
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Class I PI3K catalyzes formation of 3-poly-phosphoinositides. The family is divided into I-A isoforms, activated by Tyr kinases and I-A the I-B isoform (PI3K gamma), activated by G protein-coupled receptors. Mutations that affect PI3K are implicated in chronic inflammation, although the differential contribution of each isoform to pathology has not been elucidated. Enhanced activation of class I-A-PI3K in T cells extends CD4(+) memory cell survival, triggering an invasive lymphoproliferative disorder and systemic lupus. As both I-A- and 1(B)-PI3K isoforms regulate T cell activation, and activated pathogenic CD4(+) memory cells are involved in triggering systemic lupus, we examined whether deletion of I-B could reduce the pathological consequences of increased I-A-PI3K activity. I-B-PI3K gamma deficiency did not abolish invasion or lymphoproliferation, but reduced CD4(+) memory cell survival, autoantibody production, glomerulonephritis, and systemic lupus. Deletion of the I-B-PI3K gamma isoform thus decreased survival of pathogenic CD4(+) memory cells, selectively inhibiting systemic lupus development. These results validate the PI3K gamma isoform as a target for systemic lupus erythernatosus treatment.
引用
收藏
页码:589 / 593
页数:5
相关论文
共 50 条
  • [41] Opposing roles of endothelial and smooth muscle phosphatidylinositol 3-kinase (PI3K) in vascular contraction
    Budzyn, K
    Marley, PD
    Sobey, CG
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2005, 32 (07) : A15 - A16
  • [42] Implication of phosphatidylinositol 3-kinase membrane recruitment in hydrogen peroxide-induced activation of PI3K and Akt
    Qin, SF
    Chock, PB
    BIOCHEMISTRY, 2003, 42 (10) : 2995 - 3003
  • [43] Neprilysin facilitates adipogenesis through potentiation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway
    Juwan Kim
    Dasol Han
    Sung-Hyun Byun
    Mookwang Kwon
    Sun-Jung Cho
    Young Ho Koh
    Keejung Yoon
    Molecular and Cellular Biochemistry, 2017, 430 : 1 - 9
  • [44] Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K)
    Ito, Yoshihiro
    Hart, Jonathan R.
    Ueno, Lynn
    Vogt, Peter K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (47) : 16826 - 16829
  • [45] Neprilysin facilitates adipogenesis through potentiation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway
    Kim, Juwan
    Han, Dasol
    Byun, Sung-Hyun
    Kwon, Mookwang
    Cho, Sun-Jung
    Koh, Young Ho
    Yoon, Keejung
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2017, 430 (1-2) : 1 - 9
  • [46] Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
    Ameriks, Michael K.
    Venable, Jennifer D.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 738 - 753
  • [47] Pooled analysis of variants in the phosphatidylinositol 3-kinase (PI3K) pathway and risk of prostate cancer
    Koutros, Stella
    Schumacher, Fredrick
    Ma, Jing
    Crawford, E. David
    Huang, Wen-Yi
    Hayes, Richard
    Berndt, Sonja
    CANCER RESEARCH, 2009, 69
  • [48] Targeting phosphatidylinositol 3-kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors
    Zhu, Jingyu
    Li, Kan
    Yu, Li
    Chen, Yun
    Cai, Yanfei
    Jin, Jian
    Hou, Tingjun
    MEDICINAL RESEARCH REVIEWS, 2021, 41 (03) : 1599 - 1621
  • [49] In vitro and in vivo pharmacological properties of the potent phosphatidylinositol 3-kinase (PI3K) family inhibitor PI103
    Raynaud, F.
    Eccles, S.
    Clarke, P.
    Hayes, A.
    Di Stefano, F.
    Ahmad, Z.
    Guillard, S.
    Patel, S.
    Workman, P.
    EJC SUPPLEMENTS, 2006, 4 (12): : 172 - 172
  • [50] Phosphoinositode 3-kinaseγ (PI3Kγ) in mast cell adhesion, migration and recruitment
    Collmann, E.
    Thomas, M.
    Wymann, M. P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 : 66 - 66